This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. J. BERGAN, MD; O. H. TRIPPEL, MD; H. A. KAUPP, MD; J. C. KUKRAL, MD; W. F. NOWLIN, MD

AMA Arch Surg. 1965;91(2):338-341.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The flow of blood through the microvasculature is as vital to life as that through the heart and great vessels.

Roe Wells, Jr.

SWEDISH dextran with its molecular weight of 40,000 has been in wide use in situations of easing blood flow. Its properties are quite different from those of its American (weight, 75,000) and British (weight, 150,000) relatives. Principally, it affects a reversal of red cell aggregation and reduces blood viscosity.¹ Since this results in an increase in tissue perfusion, it has been apparent that theoretically this agent would be useful in treatment of patients with severe ischemia. Several preliminary reports have suggested some improvement of blood flow by dextran in some ischemic states.^2-4 In others, the nontoxic properties and general safety of the agents has been documented.^5,6 As a result, it has seen extensive use abroad and in this country in a remarkably diverse group . . . [Full Text PDF of this Article]

Author Affiliations
CHICAGO

From the Department of Surgery, Northwestern University School of Medicine and the Veterans Administration Research Hospital, 303 E Chicago Ave, Chicago 60611.

Footnotes
Received for publication Jan 19, 1965.

Reprint requests to 251 E Chicago Ave, Chicago 60611 (Dr. Bergan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?